Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Sherpa, Dolkar; Paudel, Bishow M.; Subedi, Bishnu H.; Chow, Robert Dobbin (2015)
Publisher: Co-Action Publishing
Journal: Journal of Community Hospital Internal Medicine Perspectives
Languages: English
Types: Article
Subjects: K2, Spice, Internal medicine, JWH-073, Case Report, STEMI, Synthetic Cannabinoids; K2; Spice; subarachnoid hemorrhage; reversible cardiomyopathy; rhabdomyolysis; STEMI; multiorgan failure; JWH-018; JWH-073, rhabdomyolysis, subarachnoid hemorrhage, JWH-018, RC31-1245, reversible cardiomyopathy, multiorgan failure, Synthetic Cannabinoids
Synthetic cannabinoids (SC), though not detected with routine urine toxicology screening, can cause severe metabolic derangements and widespread deleterious effects in multiple organ systems. The diversity of effects is related to the wide distribution of cannabinoid receptors in multiple organ systems. Both cannabinoid-receptor-mediated and non-receptor-mediated effects can result in severe cardiovascular, renal, and neurologic manifestations. We report the case of a 45-year-old African American male with ST-elevation myocardial infarction, subarachnoid hemorrhage, reversible cardiomyopathy, acute rhabdomyolysis, and severe metabolic derangement associated with the use of K2, an SC. Though each of these complications has been independently associated with SCs, the combination of these effects in a single patient has not been heretofore reported. This case demonstrates the range and severity of complications associated with the recreational use of SCs. Though now banned in the United States, use of systemic cannabinoids is still prevalent, especially among adolescents. Clinicians should be aware of their continued use and the potential for harm. To prevent delay in diagnosis, tests to screen for these substances should be made more readily available.Keywords: Synthetic Cannabinoids; K2; Spice; subarachnoid hemorrhage; reversible cardiomyopathy; rhabdomyolysis; STEMI; multiorgan failure; JWH-018; JWH-073(Published: 1 September 2015)Citation: Journal of Community Hospital Internal Medicine Perspectives 2015, 5: 27540 - http://dx.doi.org/10.3402/jchimp.v5.27540
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38: 151 78. doi: 10.1016/0378-8741(87)90061-4.
    • 2. Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow . . . and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012; 8: 15 32. doi: 10.1007/s13181-011-0202-2.
    • 3. Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 234 43. doi: 10.1016/j. pnpbp.2012.04.017.
    • 4. Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011; 128: e1622 7. doi: 10.1542/peds.2010-3823.
    • 5. Durand D, Delgado LL, de la Parra-Pellot DM, NicholsVinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use. Clin Schizophr Relat Psychoses 2013; 8: 1 13. doi: 10.3371/CSRP.DUDE.031513.
    • 6. Ukaigwe A, Karmacharya P, Donato A. A gut gone to pot: A case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med 2014; 2014: 167098. doi: 10.1155/2014/167098.
    • 7. Yu¨ cel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Archives of General Psychiatry 2008; 65: 694 701. doi: 10.1001/archpsyc.65.6.694.
    • 8. Center for Substance Abuse Research. Synthetic marijuana third most reported substance used by U.S. high school students. CESAR Fax 2013; 22(17). http://www.cesar.umd.edu/cesar/ cesarfax/vol22/22-17.pdf.
    • 9. McSherry JW. Spice, pot, and stroke. Neurology 2014; 82: 2147. doi: 10.1212/WNL.0000000000000508.
    • 10. Freeman MJ, Rose DZ, Myers MA, Gooch CL, Bozeman AC, Burgin WS. Ischemic stroke after use of the synthetic marijuana ''spice''. Neurology 2013; 81: 2090 3. doi: 10.1212/01.wnl. 0000437297.05570.a2.
    • 11. Tanei T, Morita Y, Yashima A, Wakita H, Takebayashi S, Nakahara N, et al. [Severe rhabdomyolysis and intracranial hemorrhage associated with synthetic cannabinoid: A case report]. No Shinkei Geka 2014; 42: 867 71.
    • 12. Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: What cardiologists need to know. Am J Cardiol 2014; 113: 187 90. doi: 10.1016/j.amjcard.2013.09.042.
    • 13. Gottschalk LA, Aronow WS, Prakash R. Effect of marijuana and placebo-marijuana smoking on psychological state and on psychophysiological cardiovascular functioning in angina patients. Biol Psychiatry 1977; 12: 255 e266.
    • 14. Ting JYS. Reversible cardiomyopathy associated with acute inhaled marijuana use in a young adult. Clin Toxicol (Phila) 2007; 45: 432 4. doi: 10.1080/15563650601073587.
    • 15. Kaushik M, Alla VM, Madan R, Arouni AJ, Mohiuddin SM. Recurrent stress cardiomyopathy with variable regional involvement: Insights into etiopathogenetic mechanisms. Circulation 2011; 124: e556 7. doi: 10.1161/CIRCULATIONAHA.111. 059329.
    • 16. Mukhopadhyay P, Rajesh M, Ba´tkai S, Patel V, Kashiwaya Y, Liaudet L, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res 2010; 85: 773 84. doi: 10.1093/cvr/cvp369.
    • 17. El-Subbagh H, Wittig T, Decker M, Elz S, Nieger M, Lehmann J. Dopamine/serotonin receptor ligands. Part IV [1]: Synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands. Arch Pharm (Weinheim) 2002; 335: 443 8. doi: 10.1002/1521-4184 (200212)335:9 B 443::AID-ARDP443 3.0.CO;2-U.
    • 18. Fisar Z. Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol 2010; 381: 563 72. doi: 10.1007/s00210-010-0517-6.
    • 19. Hermanns-Clausen M, Kneisel S, Szabo B, Auwa¨rter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings. Addiction 2013; 108: 534 44. doi: 10.1111/j.1360-0443.2012.04078.x.
    • 20. Bhanushali GK, Jain G, Fatima H, Leisch LJ. Thornley-Brown D. AKI associated with synthetic cannabinoids: A case series. Clin J Am Soc Nephrol 2013; 8: 5236. doi: 10.2215/CJN. 05 690612.
    • 21. Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, et al. Cannabinoid CB2 receptor potentiates obesityassociated inflammation, insulin resistance and hepatic steatosis. PLoS One 2009; 4: e5844. doi: 10.1371/journal.pone.0005844.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.